General Information
Diroximel fumarate, also known as ALKS-8700, is in Phase III clinical trials for the treatment of relapsing remitting multiple sclerosis, which is the most common form of multiple sclerosis (MS). Relapsing remitting MS is characterized by episodes of worsening neurologic functioning followed by partial or complete recovery periods free of disease progression.
About the API
Systematic name
4-O-[2-(2,5-dioxopyrrolidin-1-yl)ethyl] 1-O-methyl (E)-but-2-enedioate
Trade name(s)
(Still pending)
Technology
Synthetic
Molecular Formula
C11H13NO6 Molecular Weight
Physical properties
Solid powder
Therapeutic category
Immunology
Available formulations
Oral Solid
Regulations
US DMF
US DMF